APTA Aptamer Group Plc

REACH: non-regulatory announcement*

14 March 2024

Aptamer Group plc

("Aptamer" or the "Company")

Investor Webinar

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, announces that Dr. Arron Tolley (Chief Technical Officer) and Dr. Adam Hargreaves (Non-Executive Director) will be hosting a webinar on Thursday, 21 March 2024 at 5:30pm (GMT).

The webinar will provide investors with a valuable opportunity to interact with the Company and gain insights into the recent announcements.

There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.

You can register for the event by using the following link:

www.turnerpope.com/register

We are delighted to announce that the webinar will be chaired by experienced news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by the Company's broker, Turner Pope Investments.

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer^® platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over US$170 billion.

Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses. 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END